An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Jeffrey Hsi, a longtime physics teacher at South High School in the Valley Stream Central High School District, has been ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed ...